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Summary
Objective: To examine the effects of agonists of peroxisome proliferator-activated receptor (PPAR)  on proteoglycan degradation induced
by interleukin (IL)-1 or tumor necrosis factor (TNF) in cartilage in vitro.
Design: Proteoglycan degradation was measured as release of radioactivity from rat cartilage explants previously labeled with 35SO2−4 .
Western blots were used to examine tissue levels of aggrecan neoepitopes NITEGE and VDIPEN, generated by aggrecanases and matrix
metalloproteinases (MMP), respectively. Production of MMP-2, -3 and -9 by cultured rat chondrocytes was measured by zymography and by
fluorimetric assay.
Results: IL-1-induced proteoglycan degradation was likely due to aggrecanase, since it was associated with a strong increase of NITEGE
signal. MMP-dependent VDIPEN signal increased only after further incubation with pro-MMP activator APMA. PPAR agonists 15d-PGJ2 and
GI262570 (10 M) inhibited IL-1- and TNF-induced proteoglycan degradation measured both before and after addition of APMA. The
agonists also inhibited cytokine-induced MMP production by isolated chondrocytes.
Conclusion: This study shows that PPAR  agonists inhibit cytokine-induced proteoglycan degradation mediated by both aggrecanase and
MMP. This effect is associated with inhibition of production of MMP-3 and -9. These results support the interest for PPAR  agonists as
candidate inhibitors of pathological cartilage degradation. © 2002 OsteoArthritis Research Society International. Published by Elsevier
Science Ltd. All rights reserved.
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Peroxisome proliferator-activated receptors (PPAR) are
ligand-activated transcription factors, which belong to the
superfamily that includes nuclear receptors for steroids,
retinoids and thyroid hormone1. After binding with their
ligands, PPARs heterodimerize with 9-cis retinoic acid
receptor (RXR), and modulate transcription of target genes
through interaction with the PPAR response element
(PPRE) in their promoters. Three types of PPARs are
known (,  or , and ), with different tissue distribution,
ligand specificity and biological effects. Collectively, PPARs
play a major role in lipid and glucose metabolism and
adipocyte differentiation, but their function is not restricted
to energetic metabolism, since they are also involved in the
inflammatory process and affect proliferation, differentiated
activities and survival of various cell types1–3. PPAR  and
 were recently detected in isolated rat4 articular chondro-
cytes, and the presence of PPAR  was confirmed in
human chondrocytes either cultured5 or still embedded in
cartilage6.
Osteoarthritis (OA) is characterized by progressive
erosion of articular cartilage, and inflammatory cytokines,
such as tumor necrosis factor (TNF)  and interleukin-1673(IL-1) , probably play an important role in this process,
since they stimulate degradation and inhibit synthesis of
the two main organic components of cartilage matrix,
collagen II and aggrecan7. In addition, they activate pro-
duction of inflammatory mediators such as prostaglandin
E2, nitric oxide (NO), and radical oxygen species. IL-1 and
TNF concentrations increase in the osteoarthritic joint,
and inhibition of IL-1 activity ameliorates cartilage damage
in animal models of disease8,9. In rat and human chondro-
cytes, IL-1 decreased PPAR  expression at mRNA and
protein level4,5, which suggested that the activity of inflam-
matory cytokines could depend on inhibition of PPAR 
pathway. In agreement with this hypothesis, PPAR  agon-
ists prevented IL-1 effects on synthesis of NO, proteo-
glycan and matrix metalloproteinase (MMP)-134–6. Against
this background, we wondered if PPAR  agonists could
have a general anticatabolic action in articular cartilage,
and in particular if they could inhibit proteoglycan degra-
dation. Aggrecan, the most abundant cartilage proteo-
glycan, is cleaved by two families of metalloproteinases,
namely matrix metalloproteinases (MMP) and aggreca-
nases10. Chondrocytes express various MMPs, including
collagenases (MMP-1, -8, -13), gelatinases (MMP-2, -9),
stromelysin (MMP-3), and membrane-type MMP (MMP-
14)11. Two aggrecanases have been so far identified12,13,
and found to belong to the ADAM-TS family (a disintegrin
and a metalloproteinase with thrombospondin domain).
Aggrecanase-1 and -2 (ADAM-TS-4 and -5/-11, respec-
tively) specifically degrade proteoglycans, differently from
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REAGENTS
Dulbecco’s minimal essential medium/Ham’s F12
medium 50/50 mixture (DMEM/F12) with or without phenol
red, fetal bovine serum (FBS), Hanks’ balanced salt solu-
tion (HBSS), phosphate-buffered saline (PBS) without
Ca2+ and Mg2+, dispase, and 100×concentrated stock
solution of 104 IU/ml penicillin and 10 mg/ml streptomycin
(PS), were from GIBCO BRL (Cergy-Pontoise, France).
15d-PGJ2 and prostaglandin A2 (PGA2) were from Cayman(Ann Arbor, MI). Recombinant rat IL-1, p-aminophenyl
mercuric acetate (APMA), dimethyl sulfoxide (DMSO),
dithiothreitol (DTT), ethylenediamino tetraacetic acid
(EDTA), chondroitinase ABC, keratanase and papain were
from Sigma (Saint Quentin Fallavier, France). Recombinant
human TNF was from R&D (Abingdon, U.K.). Collagenase
type I was from Worthington (Lakewood, NJ). Antisera
against NITEGE and VDIPEN were kindly provided by
Professor Michael T. Bayliss and Dr Joanne Flannelly
(Royal Veterinary College, London). AG-3340 was provided
by Dr. Guillaume de Nanteuil at the Division of Medicinal
Chemistry of IdRS. GI262570 was provided by Professor
Daniel Lesieur, University of Lille, France. PPAR  agonists
and AG-3340 were dissolved at 2×10−2 M in DMSO, then
diluted to working concentrations in culture medium sup-
plemented with 1% FBS previously heated at 80°C for
20 min (FBS80°C) according to Parson et al.17.CARTILAGE ISOLATION
Male Wistar rat (120–150 g, Charles River, Cle´on,
France) were anesthesized under isoflurane and nitrogen
protoxide and killed by exsanguination. Ethical guidelines
for experimental investigation in animals were followed,
and the experimental protocol was used after acceptance
by the IdRS ethics committee on animal experimentation.
Articular cartilage was isolated from hips, knees andshoulders, and used for either chondrocyte isolation,
neoepitope detection, or proteoglycan degradation assays.CHONDROCYTE CULTURE
Cartilage fragments were finely minced, then digested
for 5 h at 37°C by a mixture of 3 mg/ml dispase and
2 mg/ml collagenase type I18. Isolated chondrocytes were
seeded in 24-well plates at the density of 1.2×105 cells/
well/0.5 ml of DMEM/F12 medium supplemented with 10%
FBS and 1% PS. Medium was renewed three times per
week, and after 12 days of culture, confluent cells were
washed once in HBSS, then re-fed with DMEM/F12
medium without phenol red, supplemented with 1%
FBS80°C and 1% PS. After 24 h, medium was aspirated and
cells were treated with 0.25 ml/well of the same type of
medium, containing or not containing a PPAR  agonists.
All groups were matched for agonist vehicle concentration
(DMSO). After 4 h, either IL-1, TNF or vehicle was added
and after a further 24 h conditioned media were collected
for MMP assay.MMP ZIMOGRAPHY
MMP content of conditioned media was analysed by
zymography. 40 l of sample was mixed with 10 l of 0.5 M
Tris/HCl, pH 6.8, 10% SDS, 40% glycerol, 0.1% bromo-
phenol blue. For detection of MMP-2 and -9, 10 l of
sample mixture was loaded on a 10% polyacrylamide gel
containing gelatin (Invitrogen, Paisley, U.K.). For MMP-3
detection, 20 l was loaded on a pre-stained 4–16% poly-
acrylamide gel containing casein (Invitrogen). After electro-
phoresis, gels were incubated in zymogram renaturing
buffer (Invitrogen) for 30 minutes, then in zymogram
developing-buffer (Invitrogen) for 20 h at 37°C. Gelatin-
containing gels were stained for 30 min by GelCode® blue
stain reagent (Pierce, Rockford, IL). Casein and gelatin
gels were rinsed with distilled water, then air-dried by the
DryEase system (Invitrogen). Gel images were captured
by an Agfa Arcus II scanner (Ista, Paris, France) controlled
by a Kodak 1D image analysis software (Rochester, NY,
U.S.A.).MMP FLUORIMETRIC ASSAY
Pro-MMPs in chondrocyte conditioned media were acti-
vated by addition of 2 mM APMA and incubation at 37°C for
1 h. 20 l of activated media was then added to 70 l of
zymogram developing buffer (Invitrogen) and 10 l of
0.2 mM Mca-Arg-Pro-Lys-Pro-Tyr-Ala-Nva-Trp-Met-Lys-
(Dnp)-NH2 (Bachem, Voisins les Bretonneux, France), a
fluorogenic substrate that is cleaved by MMP-2, -3 and -9 at
comparable rates19. After a 3-h incubation at 37°C, sub-
strate cleavage was measured by a cytofluor 2350 from
Millipore (St Quentin Yvelines, France) at absorption and
emission wavelengths of 340 and 440 nm, respectively.NITEGE AND VDIPEN DETECTION
Cartilage fragments were transferred to six-well plates at
a ratio of about 40 mg of tissue/5 ml of DMEM/F12 media
plus 1% FBS80°C and 1% PS, containing the agonists or
their vehicle. After 4 h, IL-1 or vehicle was added. After 2
or 3 days of culture, the media was discarded, and theMMPs, which also cleave collagens and other cartilage
components. Both aggrecanases and MMPs are synthe-
sized as proenzymes. However, while aggrecanases are
activated intracellularly through cleavage at a furin-
sensitive site12,13, soluble MMPs can be processed to the
mature form only after secretion, by plasmin, membrane-
type MMPs, or already-activated MMPs14. Aggrecanase
activity can be distinguished from that of MMPs on the
basis of different cleavage sites in the G1–G2 interglobular
domain of aggrecan15. While MMPs cleave at residues
N341–F342, aggrecanases act at E373–A374.
The aim of this in vitro study was to determine if PPAR 
agonists could inhibit proteoglycan degradation induced by
the inflammatory cytokines IL-1 and TNF in cultures of
cartilage explants. We also examined in more detail the
effects of the agonists on aggrecan degradation by MMPs
and aggrecanases. To this end, we used antibodies against
C-terminal neoepitopes of aggrecan that are generated by
aggrecanases and MMPs, NITEGE373 and VDIPEN341
respectively. These antibodies were used to examine the
content of aggrecanase- and MMP-generated neoepitopes
in IL-1-stimulated cartilage fragments. The effects of two
PPAR  agonists were examined, the natural ligand
15-deoxy-12,14-prostaglandin J2 (15d-PGJ2) and the syn-
thetic, tyrosine-based agonist GI262570, originally
designed as an antidiabetic drug16.
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dry, weighed and extracted in 3 ml of 4 M guanidinium
chloride, 5 mM EDTA, 5 mM Na acetate, pH 7.2 at 4°C for
3 days. The extract was exchanged against 5 mM EDTA
PBS and concentrated using Ultrafree and Centricon
devices (Millipore, Saint Quentin Yvelines, France) with a
MW cut-off of 10 kD. The extracts were adjusted to the
same volume/cartilage-mass ratio of 7 l/mg. The concen-
trates were deglycosylated by 0.1 U/ml of chondroitinase
ABC and keratanase at 37°C for 18 h, reduced by NuPAGE
reducing agent (Invitrogen) at 70°C for 10 min, and separ-
ated by sodium dodecylsulfate polyacrylamide gel electro-
phoresis20 on 4–12% gels (Invitrogen) in parallel with
Rainbow molecular weight markers from BioRad (Ivry sur
Seine, France), and transferred onto Hybond ECL mem-
branes (Amersham Pharmacia, Saclay, France), according
to Tsang et al.21, using a Xcell system from Invitrogen.
Membranes were saturated with 1% BSA, 0.1% Tween
(Sigma) PBS for 1 h at ambient temperature, washed in
0.1% Tween PBS, then probed with either anti NITEGE or
anti VDIPEN antisera (1/1000) in 1% BSA PBS for 1 h. After
three washes, membranes were probed with 1/2000
peroxidase-labeled anti rabbit IgG (Sigma) in 1% BSA PBS
for 1 h. After four washes, signals were visualized using an
ECL detection kit from Amersham Pharmacia. Blot images
were captured by an Agfa Arcus II scanner controlled by a
Kodak 1D image analysis software.CARTILAGE DEGRADATION
Explants from the patellar surface of femurs from
four rats were labeled with 3.7 MBq (100 Ci) of 35SO2−4(Amersham, Les Ulis, France) in 25 ml of DMEM/F12
media supplemented with 10% FBS and 1% PS. After 3
days, the unincorporated radioactivity was removed by six
media changes over 24 h using DMEM/F12 supplemented
with 1% FBS80°C and 1% PS. Each fragment was then
transferred to 96-well plates into 0.25 ml/well of the same
type of media, containing or not containing a PPAR 
agonist. All groups were matched for concentration of
agonist vehicle (DMSO). After 4 h, either IL-1, TNF or
vehicle was added. Each group was made of eight frag-
ments. After 2 or 3 more days, the fragments were collected
and digested in 0.5 ml of 0.6 mg/ml papain, 1 mM EDTA,
0.25 mg/ml DTT 20 mM sodium phosphate, pH 6.8 at 56°C
for 16 h. Radioactivity in the culture media and in the tis-
sue digest was measured by liquid scintillation using
a -counter (Beckman, Gagny, France). Proteoglycan
degradation in each fragment was expressed as the
percentage of released radioactivity by the formula:
degradation=media radioactivity/(media radioactivity+
tissue radioactivity)×100.STATISTICS
Control and treated groups were statistically com-
pared by analysis of variance followed by Dunnett’s test.
Significance was noted as follows: ***P<0.001; **P<0.01;
*P<0.05. Shown data are averages±standard error of the
mean (S.E.M.).Fig. 1. Effects of IL-1 alone (a) and (b) or IL-1 followed by APMA (c)
and (d) on proteoglycan degradation (a) and (c) and aggrecan
neoepitope levels (b) and (d) in cultured cartilage explants. A
synoptic plan of the experiment is shown at the top of the figure. In
(a) and (b), cartilage explants were cultured in control medium or
IL-1 for 2 days. Shown in (a) is degradation from day 0 to 2. In (c)
and (d), explants were further incubated for 1 day in the presence
of the MMP-activator APMA (0.5 mM). Shown in (c) is degradation
from day 2 to 3. Asterisks indicate a significant difference between
control and IL-1, without or with APMA: ***P<0.001; **P<0.01.
Data are averages±S.E.M.; N=8. Proteoglycan degradation was
measured as % release of radiolabeled material. Neoepitope
levels were assessed by western blot using anti-NITEGE and anti
VDIPEN antibodies.Results
We first determined the conditions under which proteo-
glycans are degraded in rat cartilage cultures by eitheraggrecanases or MMPs. Incubation with IL-1 for 2 days
stimulated proteoglycan degradation, measured as release
of 35SO2−4 -labeled material [Fig. 1(a)]. Western blots of
tissue extracts showed that this treatment strongly
increased aggrecanase-generated NITEGE, without any
change of MMP-generated VDIPEN [Fig. 1(b)]. Absence of
VDIPEN increase suggested that the MMPs produced in
response to IL-1 remained in the form of proenzymes. In
fact, when 2-day treatment with IL-1 was followed by
pro-MMP activation with APMA for one extra day, VDIPEN
signal was strongly increased [Fig. 1(d)]. This was associ-
ated with an augmented release of 35SO2−4 -labeled
material [Fig. 1(c)]. NITEGE signal instead disappeared
[Fig. 1(d)], in agreement with the fact that MMPs can further
cleave at position N341–F342 aggrecan fragments already
carrying the neo C terminus E373 generated by aggreca-
nase22. These results suggest that proteoglycan degra-
dation was carried out by aggrecanases in the presence
of IL-1 alone, and by MMPs when IL-1 stimulation
was followed by pro-enzyme activation using APMA. We
reasoned that, if these two treatment procedures indeed
activate two different sets of enzymes, then proteoglycan
degradation observed in the two situations will be differently
affected by inhibitors selective for either aggrecanases or
MMPs. To confirm this, we used AG-3340 (prinomastat), a
large-spectrum MMP inhibitor with Ki values between
3×10−11 and 3×10−10 M for MMP-2, -3, -9, -13 and -1423.
676 M. Sabatini et al.: PPAR agonists on cartilage degradationFig. 2. Effect of AG3340 on proteoglycan degradation induced by
IL-1 (a) or APMA following IL-1 (b). In (a) cartilage explants were
cultured from day 0 to day 2 in control medium or IL-1±AG3340;
shown is degradation between days 0 and 2. In (b) cartilage
explants were stimulated from day 0 to day 2 with IL-1, then
transferred to control medium or APMA±AG3340 for 1 further day;
shown is degradation between days 2 and 3. Proteoglycan degra-
dation was measured as % release of radiolabeled material. All
groups were matched for concentration of AG3340 vehicle
(DMSO). Asterisks indicate a significant difference between IL-1 vs
IL-1 plus AG3340, without (a) or with (b) APMA: ***P<0.001;
**P<0.01. Data are averages±S.E.M.; N=8.2Fig. 3. Effects of 15d-PGJ2 (a) and GI262570 (b) on aggrecanase-
dependent proteoglycan degradation. c: effect of 15d-PGJ2 and
GI262570 on NITEGE signal. Cartilage explants were treated for 2
days in control medium or IL-1±agonist. All groups were matched
for concentration of agonist vehicle (DMSO). Proteoglycan degra-
dation was measured as % release of radiolabeled material
between days 0 and 2. Neoepitope levels were assessed by
western blot using anti-NITEGE antibodies. Asterisks indicate a
significant difference between IL-1 vs IL-1 plus agonist:
***P<0.001; **P<0.01. Data are averages±S.E.M.; N=8.Fig. 4. Effects of 15d-PGJ2 (a) and GI262570 (b) on MMP-
dependent, proteoglycan degradation. C: effect of 15d-PGJ2 and
GI262570 on VDIPEN signal. Cartilage explants were treated from
day 0 to day 2 in control medium or IL-1±agonist, then for 1 extra
day in 0.5 M APMA. All groups were matched for concentration of
agonist vehicle (DMSO). Shown is degradation in the presence of
APMA, between days 2 and 3. Proteoglycan degradation was
measured as % release of radiolabeled material. Neoepitope
levels were assessed by western blot using anti VDIPEN anti-
bodies. Asterisks indicate a significant difference between IL-1 vs
IL-1 plus agonist: *P<0.05. Data are averages±S.E.M.; N=8.This compound also inhibits aggrecanase, but less effec-
tively, since a concentration around 1 M is needed for a
50% reduction in activity of purified enzyme24. Figure 2(a)
shows that a concentration of AG-3340 as high as 10 M
was needed to partially inhibit proteoglycan degradation
induced by IL-1 alone. However, after pro-MMP activation
by APMA, lower concentrations of the inhibitor (from 0.01 to
0.1 M) were sufficient to block the release of radiolabeled
material [Fig. 2(b)]. These results are in agreement with the
hypothesis that sequential treatment with IL-1, followed by
APMA, causes proteoglycan degradation dependent on
aggrecanase first, and then MMPs.
We then examined the effects of PPAR  agonists 15d-
PGJ2 and GI262570. From literature data, these two com-
pounds displace the radiolabeled ligand BRL49653
(rosiglitazone) from PPAR  with Ki values of 2.5×10−6 M
and 1.2×10−9 M, respectively25,26. In studies of proteogly-
can degradation, addition of 15d-PGJ2 at concentrations up
to 10 M, inhibited IL-1 effect in a dose-dependent way
[Fig. 3(a)]. A slightly lower effect was obtained with
GI262570 [Fig. 3(b)], despite its stronger affinity for
PPAR . Analysis of tissue extracts by western blot con-
firmed that 10 M 15d-PGJ2 or GI262570 prevented the
increase of NITEGE signal induced by IL-1 [Fig. 3(c)].
Next tested were the effects of the two agonists on MMP-
mediated degradation. 15d-PGJ2 significantly inhibited the
release of radiolabeled material at 10 M [Fig. 4(a)], while
the effect of GI262570 at the same concentration did not
reach statistical treshold [Fig. 4(b)]. By Western blot, the
increase of VDIPEN signal induced by IL-1 and APMA
was prevented by addition of either agonist at 10 M [Fig.
4(c)]. The specificity of the antidegradative effect of 15d-
PGJ2 was then examined by comparison with PGA2, which
despite a closely related structure, lacks any affinity for
PPAR 27. Both in the case of aggrecanase- [Fig. 5(a)] and
MMP-mediated degradation [Fig. 5(b)], only 15d-PGJ2 was
effective, PGA2 being totally inactive at concentrations up
to 10 M. We then studied the effects of the two PPAR 
agonists on the production of MMP-2, -3 and -9 in pri-
mary cultures of rat chondrocytes. Analysis of conditioned
media by gelatin and casein zymographies showed that
IL-1 stimulated production of MMP-9 and MMP-3, while
production of MMP-2 was constitutive. Addition of 15dPGJinhibited the production of MMP-3 and -9 only at the highest
concentration used, 10 M [Fig. 6(a)]. The effect of
GI262570 was weaker, in agreement with the results of
degradation assays in cartilage explants [Fig. 6(b)]. No
inhibition could be observed at lower concentrations of
either agonist, and MMP-3 signal tended even to increase
at 1 and 2.5 M. The different intensity of the effects of the
two agonists was confirmed by fluorimetric assay of MMP
activity, using a substrate cleaved by stromelysin and
gelatinases19. Also by this assay, the effect of 15d-PGJ2
Osteoarthritis and Cartilage Vol. 10, No. 9 677[Fig. 7(a)] was stronger than that of GI262570 [Fig. 7(b)].
An increase of the signal was observed, but only with
GI262570, at the lowest concentration used [Fig. 7(b)]. The
inhibitory effects of the agonists were not associated withcell toxicity, since LDH release did not increase in the
presence of either agonist at concentrations up to 10 M
(data not shown). It was finally examined if PPAR  agon-
ists could inhibit the catabolic effect of another inflamma-
tory cytokine, namely TNF. At the concentration of 10 M,
15d-PGJ2, but not GI262570, significantly inhibited proteo-
glycan degradation induced by TNF alone [Fig. 8(a)]. The
agonists also tended to inhibit degradation caused by TNF
followed by APMA, but their effects did not attain statistical
significance [Fig. 8(b)]. They also inhibited the release of
MMP-3 caused by TNF in isolated rat chondrocytes [Fig.
9(a)]. The effects of the agonist on gelatinase production
were not examined, since TNF, differently from IL-1, did
not stimulate the release of MMP-9 (data not shown).
Inhibition of MMP production by 15d-PGJ2 and GI262570
was confirmed by fluorimetric assay [Fig. 9(b)].Fig. 5. Effects of 15d-PGJ2 and PGA2 on aggrecanase-mediated(a) and MMP-mediated (b) proteoglycan degradation. Cartilage
explants were treated from day 0 to day 2 in control medium or
IL-1±15d-PGJ2 or PGA2, then further incubated for 1 day in the
presence of 0.5 M APMA. All groups were matched for concen-
tration of agonist vehicle (DMSO). Shown in (a) is degradation
between days 0 and 2; shown in (b) is degradation between days
2 and 3. Proteoglycan degradation was measured as % release of
radiolabeled material. Asterisks indicate a significant difference
between IL-1 vs IL-1 plus agonist, without (a) or with (b) APMA:
***P<0.001; **P<0.01. Data are averages±S.E.M.; N=8.Fig. 6. Effects of 15d-PGJ2 (a) and GI262570 (b) on IL-1-induced
production of MMP-2, -3 and -9 by isolated chondrocytes.
Chondrocytes were cultured for 1 day in the absence or presence
of IL-1±agonists. All groups were matched for concentration of
agonist vehicle (DMSO). Conditioned media were then analysed
by casein (MMP-3) and gelatin (MMP-2, -9) zymography.Fig. 7. Effects of 15d-PGJ2 (a) and GI262570 (b) on on
IL-1-induced production of MMPs by isolated chondrocytes.
Chondrocytes were cultured for 1 day in the absence or presence
of IL-1±agonists. All groups were matched for concentration of
agonist vehicle (DMSO). MMP activity in conditioned media was
then assayed by fluorimetric assay. Asterisks indicate a significant
difference between IL-1 vs IL-1 plus agonist: ***P<0.001;
**P<0.01; *P<0.05. Data are averages±S.E.M.; N=4.Fig. 8. Effects of 15d-PGJ2 and GI262570 on proteoglycan degra-
dation induced by TNF. Cartilage explants were treated from day
0 to day 2 (a) in control medium or TNF±agonist, then further
incubated for 1 day (b) in the presence of 0.5 M APMA. All groups
were matched for concentration of agonist vehicle (DMSO). Shown
in (a) is degradation from day 0 to day 2, and in (b) degradation
from day 2 to day 3. Proteoglycan degradation was measured as
% release of radiolabeled material. Asterisks indicate a significant
difference between TNF vs TNF plus agonist, without (a) or with
(b) APMA: **P<0.01. Data are averages±S.E.M.; N=8.Discussion
This study shows that PPAR  agonists 15d-PGJ2 and
GI262570 inhibit IL-1-induced proteoglycan degradation
mediated by both MMPs and aggrecanases in cultured
explants of rat cartilage. This effect was probably due to
inhibition of enzyme production, since PPAR  agonists
also decreased, at the highest concentration used of
10 M, the release, by isolated chondrocytes, of MMP-3
and -9, two of the metalloproteases responsible for
678 M. Sabatini et al.: PPAR agonists on cartilage degradationproteoglycan degradation in cartilage. This hypothesis is in
agreement with the finding by Fahmi et al.6, that PPAR 
agonists inhibit MMP-13 production induced by IL-1 in
human chondrocytes. Moreover, inhibition of MMP-9 was
not specific to chondrocytes, since this effect had also been
observed in macrophages28 and in a monocytic cell line29.
However, the effect of the two agonists on MMP-3 produc-
tion seemed to be biphasic, with an increase of enzyme
activity at concentrations around 1 M. This type of
response is probably specific to MMP-3, since it was not
observed either on MMP-9 by us, or on MMP-13 by Fahmi
et al.6. 15d-PGJ2 was active also against the effects of
TNF, as shown by inhibition of matrix degradation and
MMP production. Inhibition of TNF action by GI262570
was weaker than that produced by 15d-PGJ2, and did not
reach statistical significance. Throughout our study, active
concentrations of 15d-PGJ2 and GI262570 were comprised
between 1 and 10 M, the same narrow range as that
necessary to inhibit other cytokine effects such as stimu-
lation of NO and MMP-13 production, and inhibition of
proteoglycan synthesis4–6. Higher concentrations could not
be used, since they quickly resulted in shrinking and
detachment of chondrocytes from culture dishes. This
phenomenon was not further analysed, and even if its toxic
nature cannot be excluded, it suggested induction of apop-
tosis, an effect of PPAR  agonists already described in
other cell types, among which synoviocytes, endothelial
cells and fibroblasts30–32. Work is in progress to see if
antiapoptotic agents, such as caspase inhibitors, can pre-
vent at least some of the effects of PPAR  agonists in our
system. In all the experiments performed, 15d-PGJ2 was
slightly more active than GI262570, despite a lower affinity
for PPAR 25,26. This finding, although difficult to explain,
mirrors others similarly obtained on chondrocytes, in which
15d-PGJ2 was more active than PPAR  agonists troglita-
zone4,5 and BRL496536, despite lower receptor affinity and
transactivating activity27,33. In a different cell system,
GI262570 stimulated differentiation of precursor cells intoadipocytes at concentrations in the nanomolar range26.
The need for higher concentrations of synthetic agonists to
exert their effects in chondrocytes, compared with other cell
types, could be due to less efficient membrane passage
and/or transactivation of the target genes. It could be
otherwise explained by the hypothesis by Boyault et al.,
that the effects of the agonists on cartilage are independent
of PPAR 5. We showed nevertheless that the effects of
15d-PGJ2 were not aspecific, since the structurally related
compound PGA2, which has a Ki value higher than
1000 M, compared with 4 M for 15d-PGJ2 in the same
displacement assay27, did not inhibit proteoglycan degra-
dation in cartilage explants (Fig. 5), or NO production by
isolated chondrocytes (data not shown). Even if our results
do not prove that the observed anticatabolic effects were
actually due to interaction of the agonist with PPAR ,
15d-PGJ2 concentrations that proved active in our hands
are necessary for, and compatible with, the functioning of
this agonist through the PPAR-PPRE system, since Fahmi
et al., showed that concentrations of 15d-PGJ2 between 1
and 10 M dose-dependently increased the transcription of
a PPRE-driven reporter gene transfected into human
chondrocytes6. The mechanism by which PPAR  acti-
vation causes inhibition of cytokine effects in cartilage has
not been determined yet. However, it was shown that
PPAR  agonists interfere with the functioning of two tran-
scription factors that mediate the effects of inflammatory
cytokines in different cell types among which chondrocytes.
PPAR  agonists blocked the binding of AP-1 and NFkB
to DNA sequences of their response elements5,6. Similarly
to what was found in macrophages28, this could be due to
direct protein to protein interaction of PPAR  with these
transcription factors, independently of binding with PPRE.
Availability of specific and powerful antagonists of PPAR 
should allow to determine the actual involvement of the
receptor in the effects of 15d-PGJ2 on chondrocytes. In
conclusion, our results, although not conclusive about the
involved mechanism, support the hypothesis that PPAR 
can play an important role in negative control of IL-1 and
TNF transduction pathways, and confirm the interest for
PPAR  agonists as candidate inhibitors of cartilage loss in
diseases characterized by increased degradation of joint
tissues, such as rheumatoid arthritis and OA.Acknowledgments
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